Strategic partnerships Dynacure combines clinical-stage rare disease programs with a strategic collaboration framework (notably with Ionis and Nippon Shinyaku), presenting ongoing collaboration opportunities for antisense therapies and co-development or regional licensing in Japan and beyond.

Rare disease focus Target areas include Myotubular and Centronuclear Myopathies and Hereditary Spastic Paraplegias, which align with niche specialty clinics, patient advocacy groups, and CROs specializing in neuromuscular rare diseases—opportunities for investigator-led trials and compassionate-use programs.

Global access With headquarters in France and a corporate office in the US, Dynacure presents a gateway for cross-border collaborations, regional market entry strategies, and potential partnerships with US/欧 regulatory consultants to accelerate clinical programs in North America and Europe.

Financial readiness Supported by significant funding and a public listing, Dynacure has financial capacity for expansion activities, co-funding of trials, and joint development deals, making it a compelling partner for investors and strategic pharma companies seeking early-stage assets.

Technology enablement Utilizing antisense technology (DYN101) and a research portfolio approach, Dynacure seeks collaborations to optimize delivery, biomarkers, and translational research, offering opportunities for CROs, diagnostic partners, and platform vendors to contribute to trial design and companion diagnostics.